Two Sigma Investments
PTGX icon

Two Sigma Investments’s Protagonist Therapeutics PTGX Stock Holding History

Two Sigma Investments’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,741
Closed -$278K – 3465
2025
Q1 		$278K Buy
5,741
+83
+1% +$3.48K ﹤0.01% 2745
2024
Q4 		$218K Sell
5,658
-53
-0.9% -$2.31K ﹤0.01% 2849
2024
Q3 		$257K Sell
5,711
-76,926
-93% -$3.11M ﹤0.01% 2734
2024
Q2 		$2.86M Sell
82,637
-74,957
-48% -$2.2M 0.01% 1312
2024
Q1 		$4.56M Sell
157,594
-1,249
-0.8% -$34K 0.01% 1018
2023
Q4 		$3.64M Sell
158,843
-177,465
-53% -$3.11M 0.01% 1157
2023
Q3 		$5.61M Sell
336,308
-40,165
-11% -$779K 0.02% 845
2023
Q2 		$10.4M Buy
376,473
+68,773
+22% +$1.72M 0.03% 631
2023
Q1 		$7.08M Sell
307,700
-184,265
-37% -$3.09M 0.02% 742
2022
Q4 		$5.37M Buy
491,965
+246,260
+100% +$2.08M 0.02% 819
2022
Q3 		$2.07M Sell
245,705
-69,939
-22% -$662K 0.01% 1131
2022
Q2 		$2.5M Buy
315,644
+27,126
+9% +$328K 0.01% 1068
2022
Q1 		$6.83M Buy
288,518
+260,418
+927% +$7.34M 0.02% 777
2021
Q4 		$961K Buy
28,100
+3,500
+14% +$111K ﹤0.01% 2595
2021
Q3 		$436K Sell
24,600
-48,777
-66% -$2.08M ﹤0.01% 3372
2021
Q2 		$3.29M Sell
73,377
-10,139
-12% -$335K 0.01% 1481
2021
Q1 		$2.16M Sell
83,516
-72,850
-47% -$1.84M 0.01% 1650
2020
Q4 		$3.15M Sell
156,366
-63,837
-29% -$1.37M 0.01% 1206
2020
Q3 		$4.3M Sell
220,203
-69,775
-24% -$1.31M 0.02% 867
2020
Q2 		$5.12M Buy
289,978
+180,355
+165% +$2.26M 0.03% 635
2020
Q1 		$774K Sell
109,623
-94,261
-46% -$706K 0.01% 1616
2019
Q4 		$1.44M Buy
203,884
+154,463
+313% +$1.53M ﹤0.01% 1856
2019
Q3 		$594K Sell
49,421
-72,703
-60% -$916K ﹤0.01% 2412
2019
Q2 		$1.48M Buy
122,124
+76,247
+166% +$843K ﹤0.01% 1640
2019
Q1 		$577K Sell
45,877
-11,301
-20% -$99.7K ﹤0.01% 2184
2018
Q4 		$385K Sell
57,178
-87,341
-60% -$693K ﹤0.01% 2273
2018
Q3 		$1.49M Sell
144,519
-32,960
-19% -$284K ﹤0.01% 1692
2018
Q2 		$1.19M Buy
177,479
+144,679
+441% +$1.11M ﹤0.01% 2020
2018
Q1 		$282K Sell
32,800
-24,976
-43% -$470K ﹤0.01% 2813
2017
Q4 		$1.2M Buy
+57,776
New +$1.03M ﹤0.01% 1835

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments's PTGX Position: Q2 2025 in Review

Two Sigma Investments sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 5,741 shares — an estimated $278K sold.

Two Sigma Investments first reported a position in PTGX in Q4 2017 and held it in 30 quarters. The position peaked at $10.4M in Q2 2023. 273 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

  • Two Sigma Investments reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Investments sold 5,741 Protagonist Therapeutics shares in Q2 2025, an estimated $278K.
  • Two Sigma Investments first reported a position in Protagonist Therapeutics in Q4 2017 and held it in 30 quarters.
  • Two Sigma Investments's Protagonist Therapeutics position peaked at $10.4M in Q2 2023.
  • 273 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on Two Sigma Investments's 13F filing for Q2 2025, filed 14 Aug 2025.